Get the Stockscreener App
21.19
1.35%
-0.29
Quidelortho Corporation stock is traded at $21.19, with a volume of 572.57K.
It is down -1.35% in the last 24 hours and down -27.70% over the past month.
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
See More
Previous Close:
$21.48
Open:
$21.52
24h Volume:
572.57K
Relative Volume:
0.55
Market Cap:
$1.44B
Revenue:
$2.74B
Net Income/Loss:
$-441.40M
P/E Ratio:
-3.2401
EPS:
-6.54
Net Cash Flow:
$13.00M
1W Performance:
-9.17%
1M Performance:
-27.70%
6M Performance:
-23.75%
1Y Performance:
-45.62%
1-Day Range:
$20.92
$21.80
1-Week Range:
$20.59
$23.58
52-Week Range:
$19.50
$41.40
Quidelortho Corporation Stock (QDEL) Company Profile
Name
Quidelortho Corporation
Sector
Industry
Phone
(858) 552-1100
Address
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
21.19 | 1.46B | 2.74B | -441.40M | 13.00M | -6.54 |
|
ABT
Abbott Laboratories
|
113.10 | 197.42B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
381.89 | 147.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
95.60 | 124.16B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.21 | 109.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.22 | 49.49B | 6.07B | 1.06B | 1.34B | 1.8063 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-25 | Downgrade | Citigroup | Buy → Neutral |
| May-08-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Sep-19-24 | Resumed | UBS | Neutral |
| Sep-05-24 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-04-24 | Downgrade | UBS | Neutral → Sell |
| Feb-14-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-14-22 | Upgrade | UBS | Sell → Neutral |
| Sep-19-22 | Initiated | Citigroup | Neutral |
| Jul-20-22 | Initiated | UBS | Sell |
| Jun-17-22 | Resumed | JP Morgan | Neutral |
| Feb-22-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-12-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-26-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Mar-08-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-18 | Reiterated | Barclays | Overweight |
| Jan-04-18 | Upgrade | CL King | Neutral → Buy |
| Sep-19-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-18-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| Apr-25-17 | Reiterated | Canaccord Genuity | Hold |
| Feb-17-17 | Initiated | CL King | Neutral |
| Dec-16-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-13-16 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-18-16 | Reiterated | Barclays | Overweight |
| Feb-09-16 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
| Dec-14-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-02-15 | Initiated | Barclays | Overweight |
| Jul-31-13 | Reiterated | Canaccord Genuity | Buy |
| Mar-03-11 | Downgrade | Wedbush | Outperform → Neutral |
View All
Quidelortho Corporation Stock (QDEL) Latest News
American Century Companies Inc. Raises Stock Position in QuidelOrtho Corporation $QDEL - MarketBeat
Technical Analysis: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Daily Oversold Bounce Ideas - baoquankhu1.vn
QuidelOrtho at Raymond James Conference: Strategic Growth Insights - Investing.com Nigeria
QuidelOrtho at Raymond James Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
QuidelOrtho Stock Challenges: Revenue, Cash Flow, and ROIC TrendsNews and Statistics - IndexBox
A Look At QuidelOrtho (QDEL) Valuation After New Lifotronic Supply Agreement - Sahm
QuidelOrtho Corporation (QDEL) Stock Analysis: Potential Upside of Over 50% Amidst Strategic Positioning in Healthcare - DirectorsTalk Interviews
Segall Bryant & Hamill LLC Sells 71,044 Shares of QuidelOrtho Corporation $QDEL - MarketBeat
Vanguard Group Inc. Has $224.89 Million Stock Position in QuidelOrtho Corporation $QDEL - MarketBeat
QuidelOrtho (QDEL): Buy, Sell, or Hold Post Q4 Earnings? - Finviz
QuidelOrtho Corp reports results for the quarter ended March 31Earnings Summary - TradingView
QuidelOrtho (QDEL) Q4 2025 Earnings Transcript - AOL.com
QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires - The Motley Fool
QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires - The Motley Fool
QuidelOrtho Corporation (NASDAQ:QDEL) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail
Should QuidelOrtho’s (QDEL) Lifotronic Immunoassay Expansion Require Action From QDEL Investors? - simplywall.st
Why The QuidelOrtho (QDEL) Story Is Shifting As Analysts Rework Growth And Valuation Assumptions - Yahoo Finance
Is QuidelOrtho Corporation a defensive stockJuly 2025 Price Swings & Verified Swing Trading Watchlists - baoquankhu1.vn
Has QuidelOrtho (QDEL) Become A Potential Opportunity After Its Sharp Share Price Slide - simplywall.st
QuidelOrtho Corp. Stock Hits Day Low of $21.14 Amid Price Pressure - Markets Mojo
QuidelOrtho Corporation (QDEL) Stock Analysis: Exploring a 63.60% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
Earnings Miss: Is QuidelOrtho Corporation a defensive stock2025 Volatility Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know - Finviz
QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2025 earnings call transcript - MSN
Quidelortho Faces Material Risk from Weak Internal Controls and Sarbanes–Oxley Compliance Challenges - TipRanks
Decoding QuidelOrtho Corp (QDEL): A Strategic SWOT Insight - GuruFocus
Can QuidelOrtho’s (QDEL) Lifotronic Deal Reshape Its Global Immunoassay Competitiveness Story? - Yahoo Finance
Faster Cardiac Answers with High‑Sensitivity Troponin - PR Newswire
QuidelOrtho and Lifotronic agree on global immunoassay portfolio expansion - MSN
QuidelOrtho (NASDAQ:QDEL) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
QuidelOrtho Corp SEC 10-K Report - TradingView
QuidelOrtho Earnings Call: Growth, Margins And Risks - TipRanks
QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference - marketscreener.com
The Top 5 Analyst Questions From QuidelOrtho's Q4 Earnings Call - Finviz
QuidelOrtho Partnership Targets Expanded Immunoassay Reach in International Markets - TipRanks
QuidelOrtho–Lifotronic Partnership Targets Global Immunoassay Expansion - TipRanks
QuidelOrtho plans March 3 talk at Raymond James investor conference - Stock Titan
QuidelOrtho–Lifotronic Partnership Targets Immunoassay Expansion in International Markets - TipRanks
Surprises Report: Is QuidelOrtho Corporation a turnaround storyMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
The Top 5 Analyst Questions From QuidelOrtho’s Q4 Earnings Call - Yahoo Finance
QuidelOrtho Expands in Mexico With Lifotronic Deal - Mexico Business News
QuidelOrtho Expands Global Immunoassay Offering Through Lifotronic Partnership - TipRanks
QuidelOrtho Corporation (QDEL): Analyzing Its 47% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio - Finviz
QDEL stock slumps on mixed Wall Street price target revisions after Q4 report - MSN
QuidelOrtho enters strategic supply agreement to expand global immunoassay portfolio - BioSpectrum Asia
QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio – Company Announcement - Financial Times
QuidelOrtho Enters Strategic Supply Agreement with Lifotronic - Intellectia AI
QuidelOrtho Q4 results beat on both lines, but issues weak 2026 EPS guidance - MSN
Will QuidelOrtho Corporation be affected by tariffsJuly 2025 Retail & Weekly High Return Forecasts - mfd.ru
Quidelortho Corporation Stock (QDEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.27%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):